Suresh Ramalingam, MD, FASCO; Winship Cancer Institute Emory University 5Live #ASCO20
Key insights on Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
Vivek Subbiah, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO20
Key Insights on Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
Roy Herbst, MD, PhD, FACP, FASCO; Yale Cancer Center 5Live #ASCO20
Key insights on Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Natasha B. Leighl, MD, MMSc, FRCP, FASCO Princess Margaret Cancer Center, Toronto 5Live #ASCO20
Key Insights on CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
Martin Reck, MD, PhD; Lung Clinic Grosshansdorf 5Live #ASCO20
Key insights on Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Harry J. M. Groen, MD, PhD; University Medical Center Groningen 5Live #ASCO20
Key insights on Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.